PL
VRTX icon

Polianta Ltd’s Vertex Pharmaceuticals VRTX Stock Holding History

Polianta Ltd’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,400
Closed -$1.16M – 112
2021
Q1 		$1.16M Hold
5,400
– – 0.64% 39
2020
Q4 		$1.28M Buy
+5,400
New +$1.24M 0.7% 26

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Polianta Ltd's VRTX Position: Q2 2021 in Review

Polianta Ltd sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 5,400 shares — an estimated $1.16M sold.

Polianta Ltd first reported a position in VRTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.28M in Q4 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • Polianta Ltd reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Polianta Ltd sold 5,400 Vertex Pharmaceuticals shares in Q2 2021, an estimated $1.16M.
  • Polianta Ltd first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Polianta Ltd's Vertex Pharmaceuticals position peaked at $1.28M in Q4 2020.
  • 976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Polianta Ltd's 13F filing for Q2 2021, filed 6 Jul 2021.